PDCD1 and neoplasm: Lenvatinib co-treatment with anti-PD-1 therapy also leads to long-term immune memory formation while synergistically regulating the TME and tumor vascular normalization and enhancing the cytotoxic effects of T-cells, promoting therapeutic efficacy in HCC [22].